View Cart  

FDA Warning to Hospira Infusion Plant May Hint at Broader Problems

A A
An FDA warning letter issued to Hospira’s infusion pump plant in Costa Rica may be emblematic of broader companywide manufacturing issues, analysts say.

To View This Article:

Login

Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $25.00